Protocol Ledger

NCT07740564 · Phase III · RECRUITING

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

Interventional Phase III clinical trial protocol NCT07740564 sponsored by Ocumension Therapeutics (Suzhou) Co in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-25 Enrollment: 842 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07740564
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)842 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07740564
Protocol FieldVerified Registry Value
NCT IdentifierNCT07740564
Consolidated Lead SponsorOcumension Therapeutics (Suzhou) Co
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment842 participants (ESTIMATED)
Registered Start Date2026-08-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI